Welcome to an inside look at some of the impactful research taking place to improve the lives of individuals with Prader–Willi syndrome (PWS). In this interview, four FPWR research team members—Theresa Strong, Lauren Schwartz-Roth, Marc Ridilla, and Lisa Matesevac—and IPWSO Board of Trustees...
Source: FPWR Blog
|
Published: August 8 2025 - 09:00 AM
FPWR maintains the latest clinical trial information so that you can stay abreast of trial opportunities. Some trials require in-person visits, while others can be completed remotely. Some trials are testing new drugs, while others are intervention (non-drug) or natural history studies. Details of...
Source: FPWR Blog
|
Published: August 8 2025 - 08:30 AM
How should I talk with my child about their PWS diagnosis? This is a question many parents ask as their child grows, and differences between them and their typical peers may become more apparent. Will discussing the PWS diagnosis empower their child to advocate for themselves effectively, or could...
Source: FPWR Blog
|
Published: July 7 2025 - 09:00 AM
A newly published study on the use of guanfacine extended release (GXR) in individuals with Prader-Willi syndrome (PWS) marks an important step forward in addressing challenging behaviors such as aggression, skin-picking, and hyperactivity. Funded by FPWR, this was the first randomized,...
Source: FPWR Blog
|
Published: July 7 2025 - 09:00 AM
We’re excited to share that Acadia Pharmaceuticals has officially completed enrollment for its Phase 3 COMPASS PWS clinical trial of ACP-101 in individuals with Prader-Willi syndrome (PWS)—three months ahead of schedule!
Source: FPWR Blog
|
Published: July 7 2025 - 06:15 AM
